Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX
Crinetics Pharmaceuticals — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
18 slides from Crinetics Pharmaceuticals's conference presentation, Jan 13, 2026
Slide 1: Beyond Innovation to Impact: Building the Premier Endocrinology Business
JANUARY 2026 Beyond Innovation to Impact: Building the Premier Endocrinology Business J.P. Morgan Healthcare Conference Angela Living with Acromegaly
Slide 2: Forward Looking Statements and Legal Disclaimers
Forward Looking Statements and Legal Disclaimers Forward Looking Statements: This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained
Slide 3: 2025: A Breakout Year
2025: A Breakout Year Launched PALSONIFY (paltusotine) Demonstrated Early Success Commercial Towards Market Leadership Built Fully-Integrated Pharmaceutical Company Presented Positive Phase 2 Data on Atumelnant Well-Funded well Showing Potential to into 2030 Infrastructure R&D Transform CAH Treatmen
Slide 4: What's Next: Late-Stage Pipeline of Transformative Assets
What’s Next: Late-Stage Pipeline of Transformative Assets PRODUCT CANDIDATE INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATIONAL APPROVED US Patients Acromegaly (US) Paltusotine 36,0001 (Oral SST2 Agonist) Acromegaly (EU) Paltusotine Carcinoid Syndrome 18,000-34,000² (Oral SST2 Agonist) Atu
Slide 5: PALSONIFY: Strong Commercial Fundamentals Reflect Early Success
PALSONIFY: Strong Commercial Fundamentals Reflect Early Success Patients Providers Payers Activated and Adopting with Recognizing Value Motivated Confidence Proposition >200 >125 ~50% / ~50% Enrollment Forms Unique Palsonify Reimbursed vs. Quickstart Prescribers for Newly Filled Bottles 22/22 Enroll
Slide 6: Palsonify is Delivering Meaningful Patient Impact
Palsonify is Delivering Meaningful Patient Impact Megan David David Ashleigh Previously treated with combination of Previously treated with somatuline depot Previously treated with SRL injections, monthly and weekly injections, and is injections, then Mycapssa, and is now and is now on PALSONIFY. no
Slide 7: Palsonify: Potential for Blockbuster Therapy in Acromegaly
Palsonify: Potential for Blockbuster Therapy in Acromegaly Switch & Naive Return to Care Diagnose 36,000 17,000 Undiagnosed 19,000 No Active 7,500 Follow-up 10,000 Recent Treatment 1,500 Discontinued 4,500 Treatment Naïve 3,000 Injectable SRL 2,500 Other Therapies Phase 1 Phase 2 Phase 3 + 500 newly
Slide 8: Paltusotine: Blockbuster Potential for a Second Indication of Carcinoid Syndrome
Paltusotine: Blockbuster Potential for a Second Indication of Carcinoid Syndrome 18-34K people Substantial with carcinoid syndrome in the U.S. Patient treated with SRLs1 Impact Patients on painful monthly SRLs injections often have breakthrough symptoms Positive Phase 2 Data Phase 3 Trial Underway F
Slide 9: Atumelnant is Designed to Treat CAH, Reserving Glucocorticoid Use for Physiologic Replacement Only
Atumelnant is Designed to Treat CAH, Reserving Glucocorticoid Use for Physiologic Replacement Only Hypothalamic-Pituitary-Adrenal (HPA) Axis in CAH Stress Hypothalamus • Atumelnant is the first and only investigational Circadian once-daily, oral MC2R antagonist in clinical testing Clock • Selectivel
Slide 10: Atumelnant Vision: Healthier Hormone Levels for People Living with CAH
Atumelnant Vision: Healthier Hormone Levels for People Living with CAH 2500 High A4 High A4 Androstenedione Level (A4) 2000 + + Normal GC High GC 1500 (ng/dL) 1000 Normal A4 500 + Normal High GC A4 + GC 0 5 10 15 20 25 Glucocorticoid (GC) Dose (Hydrocortisone Equivalent) (mg/m2/day) A single pill ta
Slide 11: Rapid, Substantial and Sustained A4 Reductions, the Key Biomarker for CAH Disease Control
Rapid, Substantial and Sustained A4 Reductions, the Key Biomarker for CAH Disease Control GC Stable Dose, GC Dose Reduced, • All dose cohorts had substantial PM Atumelnant Dosing AM Atumelnant Dosing 1800 decreases vs. baseline, with the 40 mg 80 mg Cohort 4 80 mg 120 mg magnitude of response Mean M
Slide 12: Robust A4 Reduction Maintained with AM Dosing and Sustained with GCs Reduced to Physiologic Levels
Robust A4 Reduction Maintained with AM Dosing and Sustained with GCs Reduced to Physiologic Levels Morning Serum A4 Levels and GC Doses Over Time for Cohort 4 (80mg AM Dosing) Atumelnant GC Taper From Weeks 2-10 Stable GC Dose 14.0 Mean GC Dose (mg/m2/day) (SE) 1500 GC Dose 7/8 Achieved Mean (SE) of
Slide 13: Atumelnant Continues to be Well Tolerated with No Serious Adverse Events Reported
Atumelnant Continues to be Well Tolerated with No Serious Adverse Events Reported Phase 2 (N=38¹) OLE (N=25 to date²) (GCs reduced) Cohort 1 – 3 (N=28) (Stable GC doses) • 7 participants now have exposure ≥20 • Well tolerated, no serious adverse events and no weeks, of which 1 participant has reache
Slide 14: Atumelnant: Potential for Blockbuster Therapy in CAH
Atumelnant: Potential for Blockbuster Therapy in CAH Substantial ~12K ~5K Currently Living with Patient Adults Children CAH in the U.S. Impact Positive Phase 2 Data Phase 3 Program Underway Rapid and sustained mean A4 reductions of up to First patient randomized in December 2025 80% as soon as 2 wee
Slide 15: CRN09682: First Candidate from Crinetics' Nonpeptide Drug Conjugate Platform for SST2-Expressing Tumors
CRN09682: First Candidate from Crinetics’ Nonpeptide Drug Conjugate Platform for SST2-Expressing Tumors Differentiation vs. Current Modalities • Non-cytotoxic when linked Payload • Highly potent when free Anticancer Agents (Chemotherapies, PROTAC) • Interchangeable payload for future development X N
Slide 16: CRN09682: Potential Blockbuster for Neuroendocrine Tumors and Other SST2+ Tumors
CRN09682: Potential Blockbuster for Neuroendocrine Tumors and Other SST2+ Tumors ~11-21K people And even more Substantial with other SST2+ treated with Patient tumors (U.S.) Impact antitumor agents for NETs1 (U.S.) Promising Preclinical Data Phase 1/2 Program Underway Selectively delivered MMAE into
Slide 17: Vision 2030: Emerging as the Premier Endocrinology Business
Vision 2030: Emerging as the Premier Endocrinology Business Sustainable Growth Funded by Revenue 2 Marketed Products 4 Approved Indications 7+ Clinical Pipeline Candidates Pipeline Expansion Fueled by Internal Innovation The vision for 2030 is aspirational and subject to significant risks, including
Slide 18: THANK YOU
THANK YOU CRINETICS PHARMACEUTICALS | 18
Crinetics Pharmaceuticals — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix